74329
document
[ Effects of simvastatin on plasma lipids , lipoproteins and apoproteins ( A1 and B ) . 24 cases of major primary hypercholesterolemia ] . We studied the effects of simvastatin ( MK 733 ) , a new competitive inhibitor of HMG CoA reductase , alone and in combination with a bile acid sequestrant , cholestyramine , on serum levels of lipoproteins and apoproteins A1 and B , in 24 patients with familial hypercholesterolemia . After simvastatin treatment ( 40 mg/day ) alone for 12 weeks , serum total and low density lipoprotein cholesterol decreased by 31 and 36 percent respectively . With the addition of cholestyramine , there was a 41 per cent total decrease in serum cholesterol from the control value and a 50 percent decrease in low density lipoprotein cholesterol . After cholestyramine treatment alone for 12 weeks , serum total and low density lipoprotein cholesterol decreased by 20 percent and 29 percent respectively . With the addition of simvastatin ( 20 mg per day ) , there was a 32 percent total decrease in serum cholesterol from the control value and a 43 percent decrease in low density lipoprotein cholesterol . High density lipoprotein cholesterol remained unchanged . No major adverse effect was observed . If long term safety can be confirmed , the simvastatin-cholestyramine regimen may prove useful in heterozygous familial hypercholesterolemia .
74330
Intervention_Pharmacological
simvastatin
74331
Intervention_Pharmacological
simvastatin ( MK 733
74332
Intervention_Pharmacological
bile acid sequestrant , cholestyramine
74333
Intervention_Pharmacological
simvastatin treatment
74334
Intervention_Pharmacological
cholestyramine
74335
Intervention_Pharmacological
cholestyramine treatment
74336
Intervention_Pharmacological
simvastatin
74337
Intervention_Pharmacological
simvastatin-cholestyramine regimen
74338
Outcome_Physical
plasma lipids
74339
Outcome_Physical
lipoproteins
74340
Outcome_Physical
apoproteins
74341
Outcome_Physical
low density lipoprotein cholesterol
74342
Outcome_Physical
serum cholesterol
74343
Outcome_Other
low density lipoprotein cholesterol
74344
Outcome_Mental
.
74345
Outcome_Physical
serum total
74346
Outcome_Other
and low density lipoprotein cholesterol
74347
Outcome_Physical
serum cholesterol
74348
Outcome_Mental
density lipoprotein cholesterol
74349
Outcome_Other
High density lipoprotein cholesterol
74350
Outcome_Adverse-effects
major adverse effect
74351
Participant_Condition
hypercholesterolemia
74352
Participant_Sample-size
24
74353
Participant_Condition
familial hypercholesterolemia
74354
Participant_Condition
heterozygous familial hypercholesterolemia